Dominic Stone
Metformin is a popular anti-diabetic drug that is often administered to patients with type 2 diabetes. While it is known to produce a glucose-lowering effect, it may also cause several side effects, including muscle atrophy and joint pain. This article will explore the relationship between metformin and musculoskeletal pain, as well as its potential effects on muscle function and joint health.
| Characteristics | Values |
|---|---|
| Type of drug | Anti-diabetic |
| Drug name | Metformin |
| Type of pain | Musculoskeletal pain |
| Musculoskeletal pain sites | Back, knee, neck/shoulder |
| Type of pain | Chronic multisite pain |
| Effect of the drug on pain | Protective effect |
| Effect of the drug on osteoarthritis | Treatment |
| Effect on muscle | Muscle atrophy |
Explore related products
What You'll Learn
Metformin may protect against musculoskeletal pain
Metformin is an anti-diabetic drug that is popularly prescribed for type 2 diabetes. It is known to produce a glucose-lowering effect, which is accompanied by improvements in insulin sensitivity. However, it is also known to increase the levels of p-AMPK and myostatin, a muscle atrophy-related molecule.
Several studies have found that metformin may have a protective effect when it comes to musculoskeletal pain. A cross-sectional study with 21,889 individuals from the UK Biobank found that participants with type 2 diabetes who took metformin reported less back, neck, shoulder, and knee pain. They also had lower odds of reporting chronic multisite musculoskeletal pain. The protective effects of metformin on musculoskeletal pain seem to be stronger for women than for men.
Another study published in the European Journal of Pain in February 2021 also found that metformin may be beneficial for those who suffer from musculoskeletal pain. The study included nearly 22,000 participants with type 2 diabetes who took metformin.
In addition, metformin has been found to have potential benefits in the treatment of osteoarthritis, a degenerative joint disease characterized by pain, joint stiffness, and joint dysfunction. Metformin, as an AMPK activator, can inhibit inflammatory responses, which are involved in inducing joint pain. In a sodium iodoacetate (MIA)-induced OA rat model, metformin treatment reduced the expression of the pain-related mediator CGRP in the dorsal root ganglion (DRG).
While the research suggests that metformin may have a protective effect against musculoskeletal pain, it is important to note that the effects of metformin on muscle function are still controversial and require further investigation.
Muscle Sprains: Can They Cause Fever?
You may want to see also
Explore related products
Metformin can cause muscle atrophy
Metformin is the first-line and most widely prescribed anti-diabetic drug for patients with type 2 diabetes. It is known to produce a glucose-lowering effect that is accompanied by improvements in insulin sensitivity. However, it is also known to increase the levels of p-AMPK and myostatin, a muscle atrophy-related molecule. Myostatin is a key molecule that regulates muscle volume and triggers the phosphorylation of AMPK.
Several studies have investigated the role of metformin in muscle atrophy. One study found that metformin treatment impaired muscle function through the regulation of myostatin in skeletal muscle cells via the AMPK-FoxO3a-HDAC6 axis. The muscle-wasting effect of metformin was more evident in WT than in db/db mice, indicating that more complicated mechanisms may be involved in metformin-mediated muscular dysfunction. Another study found that metformin negatively affected the hypertrophic response to resistance training in healthy older individuals.
The effects of metformin on muscle atrophy may be related to its impact on inflammation. Metformin is known to reduce inflammation, and one study hypothesized that it would augment the muscle response. However, the results showed that metformin impaired muscle hypertrophy, suggesting that its effects on muscle atrophy may be independent of its anti-inflammatory properties.
While the exact molecular mechanism of metformin in muscle atrophy is still unclear, the current evidence suggests that it plays a role in the regulation of muscle wasting at the transcriptional level. Further research is needed to fully understand the pathways and mechanisms involved in metformin-induced muscle atrophy.
It is important to note that while metformin may contribute to muscle atrophy, it has also been associated with a reduced risk of musculoskeletal pain in people with type 2 diabetes. A cross-sectional study of 21,889 participants found that those using metformin had lower odds of musculoskeletal pain in the back, knee, and neck/shoulder regions. This protective effect was stronger among women than men.
UTI and Muscle Spasms: What's the Link?
You may want to see also
Explore related products
Metformin may help treat osteoarthritis
Metformin is an anti-diabetic drug that has been used for years in the treatment of type 2 diabetes. It has been found to have anti-inflammatory and anti-aging properties, and current research suggests that it may be beneficial in treating osteoarthritis.
Osteoarthritis is an age-related degenerative joint disease that affects over 350 million people globally. It is characterised by pain, joint stiffness, and joint dysfunction, with pathological features including cartilage damage, bone fragmentation, osteophytes, and synovitis. The disease commonly involves degeneration and loss of articular cartilage, the formation of bony redundancies at the joint edges, and reactive subchondral bone proliferation.
Inflammatory mediators induce downstream effectors, causing vasodilation, joint pain, and cartilage damage. Metformin, as an AMPK activator, can inhibit inflammatory responses by acting on several signaling pathways. In a rat model of osteoarthritis, metformin treatment reduced the expression of the pain-related mediator CGRP in the dorsal root ganglion. In addition, metformin may inhibit chondrocyte apoptosis and improve pain and other related symptoms through multiple mechanisms.
In a small randomized trial, the diabetes drug metformin provided overweight or obese patients with osteoarthritis of the knee with significantly greater pain relief than a placebo. After 6 months of treatment, those on metformin scored their knee pain a mean of 31.3 points lower than at baseline on a 100-point scale, compared to an 18.9-point average decrease in the placebo group.
While further research is needed, these findings suggest that metformin may be a novel therapeutic drug for the treatment of osteoarthritis, providing pain relief and potentially slowing down disease progression.
Understanding Muscle Loss in Thighs: Reasons and Solutions
You may want to see also
Explore related products
Metformin may cause multisite musculoskeletal pain
Metformin is a popular anti-diabetic drug that is often administered to patients with type 2 diabetes. It has been found to help improve other conditions, such as musculoskeletal pain. A study with 21,889 participants with type 2 diabetes found that those taking metformin reported less back, knee, neck/shoulder, and multisite musculoskeletal pain. The odds of musculoskeletal pain were lower for those taking metformin, with odds ratios ranging from 0.85 to 0.97 for recent pain and 0.81 to 0.93 for chronic pain.
However, it is important to note that the effect of metformin on muscle function is still controversial. While some studies have found that metformin may provide a protective effect against musculoskeletal pain, others have suggested that long-term administration of metformin can cause side effects that affect muscle function. Metformin has been found to induce muscle atrophy and wasting by increasing the levels of p-AMPK and myostatin, a muscle atrophy-related molecule.
Additionally, diabetes drugs as a class have been cautioned by the FDA to cause severe and disabling joint pain. Drugs that work by making more insulin available to the body, such as Januvia, Onglyza, Tradjenta, and Nesina, are of particular concern. Patients experiencing severe and persistent joint pain after starting a DPP-4 inhibitor are advised to contact their healthcare professional, who may consider discontinuing the drug if appropriate.
In summary, while metformin may help reduce multisite musculoskeletal pain, it may also contribute to muscle atrophy and wasting. The effects of metformin on muscle function are still not fully understood, and further research is needed to elucidate the molecular mechanisms underlying its effects on muscle health.
Cholesterol's Link to Muscle Pain and Aches
You may want to see also
Explore related products
$18.23 $19.87
Metformin may reduce chronic pain
Metformin is a drug used to treat type 2 diabetes. It has been used for 60 years and is a disease-modifying drug that reduces mTORC1 signalling to induce its effects on neuronal plasticity.
There is growing evidence of metformin's pleiotropic effects, including possible effects on pain. A cross-sectional study with 21,889 individuals from the UK Biobank found that participants using metformin had lower odds of reporting chronic multisite musculoskeletal pain. The study concluded that people with type 2 diabetes taking metformin were less likely to report back, knee, neck/shoulder, and multisite musculoskeletal pain than those not taking metformin.
Further support for metformin's potential benefits in reducing chronic pain comes from its role as an AMPK activator. AMPK activation has been shown to reduce tactile allodynia, inhibit hyperalgesic priming, and diminish the excitability of nociceptors. In a rat model of bone cancer pain, metformin treatment provided strong relief from mechanical abnormal pain by downregulating TRPV1 expression.
Additionally, metformin's inhibitory effect on nuclear factor kappa B (NF-κB) leads to a decrease in the synthesis of pro-inflammatory and pro-nociceptive proteins, such as interleukin-6 (IL-6), calcitonin gene-related peptide (CGRP), and tumour necrosis factor (TNF). By inhibiting these inflammatory mediators, metformin may help reduce joint pain and cartilage damage associated with osteoarthritis.
Overall, the available evidence suggests that metformin may reduce chronic pain, particularly in individuals with type 2 diabetes. However, further studies are needed to fully understand the underlying mechanisms and the potential benefits of metformin in treating chronic pain.
Hormonal Imbalance and Muscle Twitching: What's the Link?
You may want to see also
Frequently asked questions
While there is a lack of studies investigating the association of metformin with musculoskeletal pain, some studies have found that people with type 2 diabetes who take metformin report less back, neck, shoulder, and knee pain.
Metformin is a popularly-prescribed drug for type 2 diabetes. It is known to produce a glucose-lowering effect that is accompanied by improvements in insulin sensitivity.
The side effects of metformin are controversial and currently under investigation. However, some sources indicate that long-term administration can cause muscle atrophy and affect muscle function.
